undamentalytics Newsletter

Bausch Health Companies Inc. insider trading

Every open-market purchase and sale by Bausch Health Companies Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

No open-market insider trades reported in the last five years.

Does following Bausch Health Companies Inc.’s insiders pay?

From March 12, 2010 to November 28, 2025, 48 insiders reported 104 open-market purchases and 33 sales not made under a pre-set plan in Bausch Health Companies Inc. Twelve months after each purchase was reported, the shares were +4.3% against the S&P 500 on average (median +9.9%), over 103 purchases with a full year of prices; 60% beat the index. After sales, the shares moved +22.8% against the index over 12 months (a negative figure means selling was the right call). Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on December 2, 2010 into $4,425 by November 2, 2026, −5.0% a year. It held shares 83% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $56,150 (+11.5% a year), and held throughout $81,743 (+14.1%).

$0$50.0k$100k 201020122014201620182020202220242026 $81.7k$56.1k$4.4k
Copying Bausch Health Companies Inc.'s insidersS&P 500, same days investedS&P 500, held throughout $10,000 copying every open-market purchase by Bausch Health Companies Inc.'s insiders from December 2, 2010, before costs and taxes, marked weekly. Uninvested money earns the Treasury bill rate; the portfolio held shares 83% of the time.
Bausch Health Companies Inc.: each insider's record
InsiderRolePurchases12 months after their purchasesBeat the S&P 500Sales12 months after their salesLatest report
Farmer Ronald Harold Director 12 −31.2% (12) 33% 0 — October 22, 2015
De Schutter Richard U Director 10 +15.8% (10) 70% 0 — August 6, 2021
Paulson John Director 7 −4.9% (7) 43% 2 +46.6% (2) August 14, 2025
Kornwasser Laizer EVP, Company Group Chairman 6 +21.4% (6) 67% 0 — March 25, 2014
Provencio Norma Ann Director 4 +22.7% (4) 75% 2 +10.4% (2) September 11, 2013
Schiller Howard Bradley EVP and CFO 6 +19.6% (6) 100% 0 — November 8, 2012
Stolz Brian M. EVP, Administration and CHCO 6 +14.9% (6) 67% 0 — August 12, 2013
Papa Joseph C CHAIRMAN & CEO 5 −20.5% (5) 20% 0 — September 13, 2019
Paul Laurence E Director 4 +43.6% (4) 100% 0 — June 5, 2012
Segal Lloyd Mitchell Director 4 +40.2% (4) 100% 0 — June 18, 2013
Stevenson Katharine Berghuis Director 4 +12.3% (4) 75% 0 — December 3, 2014
Valueact Capital Management, L.P. Director 2 −4.7% (2) 50% 2 −34.3% (2) June 12, 2015
Valueact Holdings, L.P. Director 4 +14.6% (4) 75% 0 — March 16, 2017
Chouinard Michel COO, Biovail Labs.Intl SRL 0 — — 3 +142.0% (3) December 1, 2010
De Silva Rajiv Pres & COO, Specialty Pharm 1 −1.1% (1) 0% 2 +62.6% (2) November 9, 2012
Herendeen Paul EVP and CFO 3 +19.7% (3) 67% 0 — September 17, 2018
Humphries William D. President, Ortho-Dermatologics 1 −42.6% (1) 0% 2 −5.0% (2) December 8, 2020
Pearson J. Michael Chief Executive Officer 2 +9.4% (2) 100% 1 −86.8% (1) November 9, 2015
Ross Thomas W. SR. Director 3 +17.6% (3) 67% 0 — March 16, 2020
Va Partners I, LLC Director 2 +48.3% (2) 100% 1 −2.9% (1) June 7, 2012
Ackermann Christina EVP AND GENERAL COUNSEL 1 +43.8% (1) 100% 1 −69.7% (1) June 4, 2021
Chai-Onn Robert Roswell EVP, GC and Corp. Secretary 2 −7.6% (2) 0% 0 — August 23, 2013
Durham Mark Andrew SVP Human Resources 0 — — 2 +36.1% (2) May 13, 2011
Mirovsky Pavel EVP, Pres. & GM Valeant EMENA 0 — — 2 −8.2% (2) June 3, 2015
Rosiello Robert L. EVP, Chief Financial Officer 2 −94.1% (2) 0% 0 — August 3, 2015
Valueact Holdings II, L.P. Director 1 +33.1% (1) 100% 1 +33.1% (1) June 9, 2020
Von Eschenbach Andrew C. Director 2 −15.8% (2) 50% 0 — August 9, 2021
Wells William Mcdowall Director 0 — — 2 +62.3% (2) December 8, 2010
Appio Thomas Pres&Co-Head Bausch&Lomb/Int'l 1 +21.6% (1) 100% 0 — December 18, 2018
Eldessouky Sam EVP & Chief Financial Officer 0 — — 1 −64.8% (1) June 15, 2021
Fibiger Hans Christian Chief Scientific Officer 0 — — 1 +151.7% (1) March 17, 2010
Hall Susan Global Head of R&D 0 — — 1 +10.0% (1) March 8, 2012
Hassan Fred Director 1 −5.8% (1) 0% 0 — September 3, 2013
Ingram Robert Alexander Director 0 — — 1 +30.9% (1) March 3, 2011
Karabelas Argeris N Director 1 −62.5% (1) 0% 0 — August 12, 2016
Lee Frank D. Director 0 — — 1 −31.4% (1) August 22, 2025
Loberg Philip Walden Jr EVP, Interim CFO 1 −20.4% (1) 0% 0 — June 13, 2011
Mayer Christine SVP, BTA Pharmaceuticals, Inc. 0 — — 1 +72.9% (1) August 10, 2010
Mckenna Mark C. President, Salix 0 — — 1 −44.3% (1) August 21, 2019
Miller Steven D Director 1 −57.6% (1) 0% 0 — December 2, 2021

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). The 40 most active of 48 insiders are shown. A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

When several insiders traded Bausch Health Companies Inc.

Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Bausch Health Companies Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 15 buying crowds with six months of prices, it averaged −4.1% against the index. After 2 selling crowds, −11.6%. One company's history is too short to judge by; the test across every company is the better guide.

MonthCrowd3 months on, vs S&P 5006 months12 months
September 30, 20212 buying−12.5%−23.9%−59.8%
June 30, 20213 selling−5.8%−17.0%−60.9%
March 31, 20204 buying−2.2%−34.0%+48.5%
September 30, 20192 buying+26.0%−16.9%−46.1%
September 28, 20183 buying−14.5%−2.3%−26.2%
March 29, 20183 buying+43.4%+46.1%+46.7%
November 30, 20172 buying−11.3%+26.7%+39.5%
March 31, 20173 buying+53.8%+22.3%+29.3%
June 30, 20162 buying+21.4%−38.0%−31.9%
September 30, 20152 buying−50.7%−93.4%−100.4%
June 30, 20153 buying−20.7%−56.2%−93.4%
December 31, 20144 buying+37.8%+57.9%−30.2%

Colours show whether the crowd was right: green when buyers were followed by a rise above the index, or sellers by a fall below it. Latest 12 of 17. Total returns from the month end; past patterns are not a forecast.

← Back to Bausch Health Companies Inc. · Funds · Politicians